Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
出版年份 2019 全文链接
标题
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
作者
关键词
-
出版物
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-27
DOI
10.1007/s40261-019-00820-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
- (2019) Weiting Liao et al. JOURNAL OF MEDICAL ECONOMICS
- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma
- (2019) XiaoMin Wan et al. JAMA Oncology
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
- (2019) Bernard Escudier NEW ENGLAND JOURNAL OF MEDICINE
- Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Jiasian Teh et al. EUROPEAN UROLOGY
- Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis
- (2019) Seye Abogunrin et al. Future Oncology
- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- (2018) Thomas Powles et al. EUROPEAN UROLOGY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
- (2018) Guohai Shi et al. JOURNAL OF MEDICAL ECONOMICS
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
- (2018) M Gross-Goupil et al. ANNALS OF ONCOLOGY
- Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
- (2018) Bin Wu et al. Journal for ImmunoTherapy of Cancer
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
- (2015) S. Bracarda et al. ANNALS OF ONCOLOGY
- A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study
- (2015) Xiaomin Wan et al. PLoS One
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Current and future systemic treatments for renal cell carcinoma
- (2012) Rosalie Fisher et al. SEMINARS IN CANCER BIOLOGY
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
- Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
- (2009) Martin Hoyle et al. VALUE IN HEALTH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now